A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Datopotamab deruxtecan (Primary) ; Durvalumab (Primary) ; Rilvegostomig (Primary) ; Volrustomig (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic
- Acronyms TROPION-Lung04
- Sponsors AstraZeneca
- 15 Dec 2023 Planned number of patients changed from 232 to 321.
- 12 Sep 2023 Result of Interim analysis from TROPION-Lung04 presented at the 24th World Conference on Lung Cancer
- 10 Sep 2023 According to a Daiichi Sankyo Company media release, Saiama Waqar, MD is an investigator in the trial.